Free Seo Webmaster Tools + Free Article Submissions | Pfizer layout "Lipitor after Time"

Kindler said: "3 years ago, we are 90 years of success the last century example of pharmaceutical companies, especially in developed countries, basic health care and heavy drugs. Wyeth acquisition is a transformation, due to a series of decision-making programs have been identified, so mergers and acquisitions quickly. "But the industry are skeptical, they think that the acquisition is to delay Lipitor patent expires impact, rather than internal reform. Pfizer CEO Kindler picture shows the CBI in the UK last year, addressing the annual meeting, the meeting theme is "Road to recovery."

Performance with support Pfizer's global best-selling drugs Lipitor patents expire, how to be prepared in advance to make up for Lipitor patent expires, causing huge economic losses, is Jeffrey? Kindler (Jeffrey

Kindler) new position of the biggest exam. College Entrance Examination around the corner, his hand over the "respondents" aroused widespread curiosity in the industry. Late last year, " Financial Times "reporter AndrewJack he visited for this purpose.

AndrewJack not the first time to visit Kindler, back in the spring of 2006 they met. At that time, Lipitor patent expires danger has begun to make investors uneasy, was still competitive, CEO Kindler post even more quiet than the other two executives. December 2008 goodbye, as Pfizer CEO Kindler has been 2 years, and its former CEO Hank McKinnell when the company (McKinnell) has retired, the other two competitors were CEO left the company, Pfizer is conducting a series of restructuring, but the fundamental issue is not resolved, the company fell.

The meeting coincided with the economic crisis, the U.S. president promised to reduce drug prices by medical reform, written for the general development of new drugs fail due Gengrang alternative enterprises worse. But Kindler seems well prepared, he said: "Once there is no (Lipitor) patent, the effect will be obvious ... ... but that day come sooner or later, our job is to adjust the company's structure to adapt to this situation." In AndrewJack view, Kindler is suggesting that it has completed a strategic plan accordingly.

To give up is painful 2006 12 months of a Saturday morning, Kindler is on family practice to prepare for the daughter's birthday, muffin, president of Pfizer Global R & D JohnLaMattina phone destroyed his good mood: the study of drug torcetrapib (expected could increase the "good Cholesterol ") The clinical trial data showed that the drug may increase mortality. Kindler recalls:" Once I know these figures, only one second to do this decision: Obviously we have to stop doing this test ... ... decision is not difficult, but it is a painful decision. "

Torcetrapib is not only a test drug, which related to Pfizer's life and death, the original idea is: it can not only separate Sell , But also with the composition of compound drug Lipitor to extend Lipitor's patent protection. Early clinical trials have shown, torcetrapib hopefully be successful, Pfizer CEO Hank McKinnell was immediately positioned as it's core business plan. Have guessed that after 3 months, Kindler will witness the demise of this strategic plan.

That same year, Merck's simvastatin (Zocor) patent expires, Generic Serious impact on its low price sales of Lipitor. Although the efficacy of Lipitor may be better, but the doctors more willing to prescribe cheaper generic drugs, generic drugs What seems to be as effective: In 2005, the German Institute for quality and efficiency of health treatment (Germany'sInstituteforQualityandEfficiencyinHealthcare, an official advisory body), said Li general effect of not properly better than the other statins, as Lipitor sales in Germany sentenced to death. In other countries, the new statins are gradually misappropriation Lipitor's market share, their efficacy and equivalent or better Lipitor, such as AstraZeneca may be (Crestor), while in India, Ranbaxy (Ranbaxy ) led several generic drug companies are global companies sued to try to overthrow the Lipitor patent, to promote their own low-cost generic drugs.

Pfizer also encountered other problems. April 2007, due to lack of patient recognition, Pfizer had to give up to spend 3 billion U.S. dollars of insulin aerosol inhaler Exubera. With other drugs, have faced patent expirations, Pfizer's product line of increasingly weak.